Cellares Secures $255M in Series C Funding to Revolutionize Cell Therapy Manufacturing

Cellares, a pioneering force in the biomanufacturing landscape, has announced a significant funding milestone, securing $255 million as part of its ongoing efforts to transform the production of cell therapies. As the first Integrated Development and Manufacturing Organization (IDMO) dedicated to an Industry 4.0 approach, Cellares is at the forefront of revolutionizing how living drugs are developed and manufactured. The funding will further enhance the company’s innovative Cell Shuttle technology, which integrates the necessary automation to execute the entire cell therapy manufacturing process in a flexible and high-throughput environment. This investment underscores Cellares’ commitment to delivering comprehensive solutions that ensure accelerated access to life-saving therapies for patients worldwide. The Cell Shuttles will be deployed across Cellares’ Smart Factories globally, facilitating mass production to meet growing patient demand and enabling lifecycle management of cell therapies with unprecedented efficiency. With over $355 million raised to date and a robust platform that lowers manufacturing costs while improving process reliability, Cellares is well-positioned to partner with academic institutions, biotech firms, and pharmaceutical companies to accelerate drug development and commercialization. Headquartered in South San Francisco, with a commercial-scale IDMO Smart Factory located in Bridgewater, New Jersey, Cellares continues to solidify its leadership in the cell therapy industry. This funding round marks a critical step in advancing its mission to revolutionize the manufacturing landscape and improve global health outcomes.